PD-1 | ApexOnco - Clinical Trials news and analysis

“The insights provided by the analysts are great”

Director New Product Planning

Morphosys

Click here for more information

Regulatory

27 November 2024

Data insights

27 November 2024

Trial results

19 November 2024

Deals

14 November 2024

For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.

Deals

29 October 2024

Regulatory

28 October 2024

Deals

18 October 2024

Data insights

14 October 2024

Conferences Data insights

10 October 2024

Trial results

9 October 2024

Subscribe to PD-1

Recent Quick take